CATEGORY

DNA Vaccines

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike DNA Vaccines.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Category Alerts

CATEGORY ALERTS

Touchlight and Pfizer have signed a patent licence agreement for the use of Touchlight dbDNA in the development of Pfizer mRNA-based vaccines, therapeutics, and gene therapies.

July 21, 2022
alert level: Medium
CATEGORY ALERTS

Touchlight and Pfizer have signed a patent licence agreement for the use of Touchlight dbDNA in the development of Pfizer mRNA-based vaccines, therapeutics, and gene therapies.

July 21, 2022
alert level: Medium
CATEGORY ALERTS

Touchlight and Pfizer have signed a patent licence agreement for the use of Touchlight dbDNA in the development of Pfizer mRNA-based vaccines, therapeutics, and gene therapies.

July 21, 2022
alert level: Medium

Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on DNA Vaccines

DNA Vaccines Market Monitoring Dashboard

Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

DNA Vaccines Industry Benchmarks

Savings Achieved

(in %)

The average annual savings achieved in DNA Vaccines category is 5.40%

Payment Terms

(in days)

The industry average payment terms in DNA Vaccines category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    DNA Vaccines Suppliers

    688
    Total Suppliers
    45
    Diverse Suppliers
    73
    Normalized Supplier Rating
    DNA Vaccines Supplier

    Find the right-fit dna vaccines supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211
    D&B SER Rating
    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile
    Company and Sector Performance
    36
    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77
    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked
    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    DNA Vaccines market report transcript

    DNA Vaccines Global Market Outlook:

    Market Growth:

    CAGR Growth Rate: 26–28 percent between 2019 and 2025.

    2019 Market Value: $1.2 billion.

    Market Drivers:

    • Rising prevalence of cancer and infectious diseases
    • Technical expertise and large-scale manufacturing scalability
    • Strategic collaborations between pharma and ARO
    • Advances in delivery mechanism of DNA vaccines through nanotechnology

    Porter's Analysis on DNA Vaccines

    Supplier Power

    • Supplier understanding of manufacturing synthetic DNA, pDNA, and developing a preprimary DNA platform gives them an upper hand. Also, there is a huge FTE rate gap among Europe (except eastern Europe) and the US-based suppliers from their counterparts in India and China

    Barriers to New Entrants

    • Expertise, technology, and cost are the components driving the category in general, so any new entrant with a particular expertise in a therapeutic area or with adoption of new technology, start working as an independent entity
    • Many of the suppliers are an offshoot of the bigger enterprises

    Intensity of Rivalry

    • The DNA vaccine market is a fragmented in veterinary medicine, dominated by tier-1 companies, while the human DNA vaccine market is still at its infancy and dominated by niche players and research institutes

    Threat of Substitutes

    • Other vaccine development platforms: Alternative vaccine development platforms for instance those that are mRNA based, GreVac (TM), a genetic platform that can expedite the vaccine delivery and production, Tonix’s proprietary horsepox vaccine platform, etc., could hamper this particular market

    Buyer Power

    • Pharma companies are leveraging low- cost countries (mostly, India and China) to consolidate on services, like custom synthesis, analytical testing, and manufacturing. Lower cost and process efficiency are given the highest priority in this type of outsourcing. FFS or FTEs are the most adopted contract models for this type of outsourcing

    Latest: Reshoring May Lead to More High-End Manufacturing in the U.S. Read Now

    Read Now